4-氰基-4-邻甲苯哌啶-1-羧酸叔丁酯 | 186347-28-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-氰基-4-邻甲苯哌啶-1-羧酸叔丁酯
• 中文别名: 1-Boc-4-氰基-4-(2-甲基苯基)哌啶
• 英文名称: 4-cyano-N-(1,1-dimethylethoxy)carbonyl-4-(2-methylphenyl)-piperidine
• 英文别名: 1-Boc-4-cyano-4-(2-methylphenyl)-piperidine；tert-butyl 4-cyano-4-(2-methylphenyl)piperidine-1-carboxylate
• CAS: 186347-28-4
• 化学式: C₁₈H₂₄N₂O₂
• 分子量: 300.401
• InChiKey: SSEBAGFBPWSVQR-UHFFFAOYSA-N

物化性质

• 沸点：
  438.8±45.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  53.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氰基-4-邻甲苯哌啶-1-羧酸叔丁酯 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 生成 N-(3-aminopropyl)-4-cyano-4-(o-tolyl)piperidine
  参考文献：
  名称：

  Phenylacetamides as selective α-1A adrenergic receptor antagonists

  摘要：

  A novel class of potent and selective or-la receptor antagonists has been identified. The structures of these antagonists were derived from truncating the 4-aryl dihydropyridine subunit present in known alpha-1a antagonists. The design principles which led to the discovery of substituted phenylacetamides, the synthesis and SAR of key analogues, and the results of select in vitro and in vivo studies are described. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00307-3
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 sodium hydride 、 sodium hydroxide 作用下， 以 Pionier 2076 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 24.0h， 生成 4-氰基-4-邻甲苯哌啶-1-羧酸叔丁酯
  参考文献：
  名称：

  [EN] SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
  [FR] PIPÉRIDINES SUBSTITUÉES QUI ACCROISSENT L'ACTIVITÉ DE P53, ET UTILISATIONS DE CES COMPOSÉS

  摘要：

  本发明提供了如下所述的化合物的化学式（1）或其药学上可接受的盐、溶剂合物或酯。这些化合物可用作HDM2蛋白的抑制剂。还公开了包含上述化合物的药物组合物以及使用它们治疗癌症的方法。

  公开号：

  WO2011046771A1

文献信息

• Oxazolidinones useful as alpha 1A adrenoceptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US06319932B1

  公开（公告）日：2001-11-20

  Novel oxazolidinone compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

  披露了新型恶唑烷酮化合物及其可药用的盐。这些化合物的合成及其作为α1a肾上腺素能受体拮抗剂的使用也进行了描述。这些化合物的一个应用是治疗良性前列腺增生。这些化合物在选择性地放松富含α1a受体亚型的平滑肌组织的能力方面是特异的，同时不引起低血压。这样的组织之一位于尿道内衬周围。因此，这些化合物的一个用途是为准切缓解患有良性前列腺增生的男性的症状，通过允许更顺畅的尿液流动。这些化合物的另一个用途是与人类5-α还原酶抑制剂化合物结合使用，从而使良性前列腺增生的急性症状和慢性症状均可得到缓解。
• Alpha 1a adrenergic receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US05922722A1

  公开（公告）日：1999-07-13

  This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These componds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

  这项发明涉及某些新颖化合物及其衍生物，它们的合成以及它们作为选择性α 1a 肾上腺素能受体拮抗剂的用途。这些化合物的一个应用是用于治疗良性前列腺增生。这些化合物在其能够放松富含α 1a 受体亚型的平滑肌组织方面具有选择性，同时不会引起低血压。这样的组织之一就是围绕尿道内膜的组织。因此，这些化合物的一个用途是为患有良性前列腺增生的男性提供急性缓解，使尿液流动更加顺畅。这些化合物的另一个用途是与人类5-α还原酶抑制剂化合物结合，从而实现对良性前列腺增生影响的急性和慢性缓解。
• Oxazolidinones useful as alpha 1a adrenoceptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US06228870B1

  公开（公告）日：2001-05-08

  Novel hydroxymethyl- and alkoxymethyl-oxazolidinone compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

  揭示了新型羟甲基和烷氧基甲基噁唑烷酮化合物及其药用可接受盐。描述了这些化合物的合成及其作为α1a肾上腺素能受体拮抗剂的用途。这些化合物的一个应用是用于治疗良性前列腺增生症。这些化合物在放松富含α1a受体亚型的平滑肌组织方面具有选择性，同时不引起低血压。这样的组织包括尿道内膜周围的组织。因此，这些化合物的一个用途是为患有良性前列腺增生症的男性提供急性缓解，从而减少尿液流动的阻碍。这些化合物的另一个用途是与人类5-α还原酶抑制剂化合物结合，以实现对良性前列腺增生症影响的急性和慢性缓解。
• Alpha-1a adrenergic receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US05661163A1

  公开（公告）日：1997-08-26

  This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

  本发明涉及某些新型化合物及其衍生物，它们的合成以及它们作为选择性α-1a肾上腺素受体拮抗剂的用途。这些化合物的应用之一是用于治疗良性前列腺增生症。这些化合物在其选择性松弛富含α 1a受体亚型的平滑肌组织的能力方面是具有选择性的，而不会同时引起直立性低血压。这样的组织可以在尿道内膜周围找到。因此，这些化合物的一个用途是为患有良性前列腺增生症的男性提供急性缓解，使尿液流动更加顺畅。这些化合物的另一个用途是与人类5α-还原酶抑制剂化合物结合使用，从而实现良性前列腺增生症的急性和慢性缓解效果。
• SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF
  申请人：Bogen Stephane L.

  公开号：US20120208844A1

  公开（公告）日：2012-08-16

  The present invention provides a compound of Formula (1) as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

  本发明提供了一种如下式（1）所述的化合物或其药学上可接受的盐，溶剂或酯。该化合物可用作HDM2蛋白的抑制剂。还揭示了包含上述化合物的药物组合物以及使用它们治疗癌症的方法。